Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tracy Robson

Showing results (71-80 of 79) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 79 results.
Plos One|February 18, 2015
Vasoactivity of rucaparib, a PARP-1 inhibitor, is a complex process that involves myosin light chain kinase, P2 receptors, and PARP itselfCian M McCrudden, Martin G O'Rourke, Kim E Cherry, et al.
Oncotarget|January 23, 2016
PTEN deficiency promotes macrophage infiltration and hypersensitivity of prostate cancer to IAP antagonist/radiation combination therapyChris W D Armstrong, Pamela J Maxwell, Chee Wee Ong, et al.
Frontiers in Oncology|October 4, 2021
Effect of the Rehabilitation Program, ReStOre, on Serum Biomarkers in a Randomized Control Trial of Esophagogastric Cancer SurvivorsSusan A Kennedy, Stephanie L Annett, Margaret R Dunne, et al.
British Journal of Cancer|November 28, 2019
FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancerStephanie Annett, Gillian Moore, Amy Short, et al.
The Journal of Clinical Endocrinology and Metabolism|July 4, 2020
Role of A Novel Angiogenesis FKBPL-CD44 Pathway in Preeclampsia Risk Stratification and Mesenchymal Stem Cell TreatmentNaomi Todd, Ross McNally, Abdelrahim Alqudah, et al.
Oncotarget|April 25, 2015
FKBPL: a marker of good prognosis in breast cancerLaura Nelson, Hayley D McKeen, Andrea Marshall, et al.
Nature Communications|March 6, 2021
Mitochondrial arginase-2 is essential for IL-10 metabolic reprogramming of inflammatory macrophagesJennifer K Dowling, Remsha Afzal, Linden J Gearing, et al.
British Journal of Pharmacology|December 20, 2023
The Concise Guide to PHARMACOLOGY 2023/24: EnzymesStephen P H Alexander, Doriano Fabbro, Eamonn Kelly, et al.
British Journal of Pharmacology|December 29, 2025
The Concise Guide to PHARMACOLOGY 2025/26: EnzymesStephen P H Alexander, Doriano Fabbro, Alasdair J Gibb, et al.
Pageof 8

Showing results (71-80 of 79) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 79 results.
Plos One|February 18, 2015
Vasoactivity of rucaparib, a PARP-1 inhibitor, is a complex process that involves myosin light chain kinase, P2 receptors, and PARP itselfCian M McCrudden, Martin G O'Rourke, Kim E Cherry, et al.
Oncotarget|January 23, 2016
PTEN deficiency promotes macrophage infiltration and hypersensitivity of prostate cancer to IAP antagonist/radiation combination therapyChris W D Armstrong, Pamela J Maxwell, Chee Wee Ong, et al.
Frontiers in Oncology|October 4, 2021
Effect of the Rehabilitation Program, ReStOre, on Serum Biomarkers in a Randomized Control Trial of Esophagogastric Cancer SurvivorsSusan A Kennedy, Stephanie L Annett, Margaret R Dunne, et al.
British Journal of Cancer|November 28, 2019
FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancerStephanie Annett, Gillian Moore, Amy Short, et al.
The Journal of Clinical Endocrinology and Metabolism|July 4, 2020
Role of A Novel Angiogenesis FKBPL-CD44 Pathway in Preeclampsia Risk Stratification and Mesenchymal Stem Cell TreatmentNaomi Todd, Ross McNally, Abdelrahim Alqudah, et al.
Oncotarget|April 25, 2015
FKBPL: a marker of good prognosis in breast cancerLaura Nelson, Hayley D McKeen, Andrea Marshall, et al.
Nature Communications|March 6, 2021
Mitochondrial arginase-2 is essential for IL-10 metabolic reprogramming of inflammatory macrophagesJennifer K Dowling, Remsha Afzal, Linden J Gearing, et al.
British Journal of Pharmacology|December 20, 2023
The Concise Guide to PHARMACOLOGY 2023/24: EnzymesStephen P H Alexander, Doriano Fabbro, Eamonn Kelly, et al.
British Journal of Pharmacology|December 29, 2025
The Concise Guide to PHARMACOLOGY 2025/26: EnzymesStephen P H Alexander, Doriano Fabbro, Alasdair J Gibb, et al.
Pageof 8